Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Trial details
- Registry ID
- NCT03624010
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Levosimendan 2.5 mg/mL Injectable Solution
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 | TENX | Phase 2 | Completed | 2023-04-25Actual |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603 | TENX | Phase 2 | Completed | 2020-04-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |